Prostate Cancer

Up to 30% of men with prostate cancer could meet criteria for genetic evaluation for hereditary disease. The challenge is separating the mutations that are relevant from those that are not.

Deborah A. Bradley, MD, oncologist, Levine Cancer Institute, discusses next steps for research in nonmetastatic prostate cancer.

James Kearns, MD, assistant professor of medicine, Levine Cancer Institute, discusses adverse events associated with surgery in patients with high-risk prostate cancer.

Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, Atrium Health, discusses pivotal clinical trials in metastatic castration-sensitive prostate cancer.

Scott T. Tagawa, MD, discusses an emerging treatment modality for patients with progressive metastatic castration-resistant prostate cancer.

Higher survival rates were observed with radical prostatectomy and adjuvant radiotherapy compared with radiotherapy and androgen deprivation therapy in men with locally advanced prostate cancer.

A panel of experts has recommended hypofractionated radiation as an alternative to longer, conventional courses of radiation for men with earlystage prostate cancer who opt for external beam radiation therapy.

Michael J. Morris, MD, medical oncologist, clinical director, Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the use of prostate-specific membrane antigen (PSMA)-targeted imaging in patients with metastatic castration-resistant prostate cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use granted support for approval of apalutamide for the treatment of adult patients with nonmetastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease.

Deborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the importance of exercise in the management of prostate cancer treatment-related adverse events.